Emerging evidence converts HPV vaccination from infection control to cancer prevention in men

New studies reveal that HPV vaccines significantly reduce persistent infections and HPV-related cancers in men, redefining vaccination as a broader public-health measure beyond female protection.

HPV vaccination is still widely associated with preventing cervical cancer, but a growing body of research is making the case that boys and men stand to benefit too. New studies suggest the vaccine can cut persistent infections in males, including infections from virus types linked to cancer, strengthening the view that HPV prevention should be understood as a broader public-health measure rather than a female-only issue.

One randomised trial in Japan, highlighted by the National Cancer Institute, followed more than 1,000 men and found that the nine-valent vaccine prevented 92% of persistent infections caused by HPV types covered by the shot. It also appeared to offer some protection against other types, though to a lesser degree. That matters because HPV infections often clear on their own, but persistent infections are the ones that can lead to cell changes and, over time, cancer.

Evidence from younger men points in the same direction. Researchers in Canada, according to the studies summarised in the supplied material, tracked nearly 1,200 gay and bisexual men aged 16 to 23 and found that those vaccinated by age 23 were 60% less likely to have anal HPV infections than those who had not been vaccinated. The benefit was not seen in men vaccinated at 27 or older, underlining why experts consistently stress early vaccination, before exposure is likely.

A broader review of 21 studies published between 2007 and 2024 also found that HPV vaccination reduced anal, penile and oral HPV infections in men. A separate review on PubMed reported that the vaccine can help prevent genital warts and persistent HPV infection in HPV-naïve men, while the National Cancer Institute said the findings add to evidence that vaccination can protect against diseases affecting the anus, penis and throat.

That wider protection matters because HPV is linked to several cancers in men, including cancers of the anus and penis, as well as oropharyngeal cancer in the back of the throat. The Centres for Disease Control and Prevention says HPV vaccination is recommended for children at 11 or 12 and can reduce infections with the HPV types responsible for most HPV-related cancers and genital warts. The CDC also notes that men face HPV-related cancer risks in the penis, anus and oropharynx.

The newest research does not yet answer the biggest question: how many cancers vaccination prevents over a lifetime. Most of the recent studies measured infection rather than long-term cancer outcomes, which take years to appear. Still, the direction of travel is clear. A separate study cited by the American Cancer Society found lower cancer risk among vaccinated people, and modelling work from the National Institute of Standards and Technology suggested that much of the preventable oral HPV exposure occurs by age 26, leaving less room for benefit later in life. Together, the evidence supports a simple message: for boys and men, HPV vaccination is increasingly looking like cancer prevention, not just infection control.